Filtered By:
Therapy: Chemotherapy
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 71193 results found since Jan 2013.
The potential therapeutic applications of CRISPR/Cas9 in colorectal cancer
Curr Med Chem. 2023 Sep 15. doi: 10.2174/0929867331666230915103707. Online ahead of print.ABSTRACTThe application of the CRISPR-associated nuclease 9 (Cas9) system in tumor studies has led to the discovery of several new treatment strategies for colorectal cancer (CRC), including the recognition of novel target genes, the construction of animal mass models, and the identification of genes related to chemotherapy resistance. CRISPR/Cas9 can be applied to genome therapy for CRC, particularly regarding molecular-targeted medicines and suppressors. This review summarizes some aspects of using CRISPR/Cas9 in treating CRC. Furth...
Source: Current Medicinal Chemistry - September 19, 2023 Category: Chemistry Authors: Toktam Sahranavard Shima Mehrabadi Ghazaleh Pourali Mina Maftooh Hamed Akbarzade Seyed Mahdi Hassanian Majid Ghayour Mobarhan Gordon A Ferns Majid Khazaei Amir Avan Source Type: research
Impact of adjuvant chemotherapy on long-term overall survival in patients with high-risk stage II colon cancer: a nationwide cohort study
CONCLUSION: 5-year overall survival was significantly higher in patients with high-risk stage II colon cancer treated with adjuvant chemotherapy compared with no chemotherapy. Adjuvant treatment was given to less than half of the patients who were eligible for it.PMID:37725517 | DOI:10.1080/0284186X.2023.2251086
Source: Acta Oncologica - September 19, 2023 Category: Cancer & Oncology Authors: Victoria Rosberg Mikkel Jessen Camilla Qvortrup Henry George Smith Peter-Martin Krarup Source Type: research
Functionalized manganese iron oxide nanoparticles: a dual potential magneto-chemotherapeutic cargo in a 3D breast cancer model
Nanoscale. 2023 Sep 19. doi: 10.1039/d3nr02816j. Online ahead of print.ABSTRACTLocalized heat generation from manganese iron oxide nanoparticles (MIONPs) conjugated with chemotherapeutics under the exposure of an alternating magnetic field (magneto-chemotherapy) can revolutionize targeted breast cancer therapy. On the other hand, the lack of precise control of local temperature and adequate MIONP distribution in laboratory settings using the conventional two-dimensional (2D) cellular models has limited its further translation in tumor sites. Our current study explored advanced 3D in vitro tumor models as a promising altern...
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Satish S Phalake Sandeep B Somvanshi Syed A M Tofail Nanasaheb D Thorat Vishwajeet M Khot Source Type: research
Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair
CONCLUSIONS: In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increase the therapeutic success.PMID:37725585 | DOI:10.1158/1078-0432.CCR-23-1795
Source: Clinical Lung Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Anna Solta Kristiina Boettiger Ildik ó Kovács Christian Lang Zsolt Megyesfalvi Franziska Ferk Miroslav Mi šík Konrad Hoetzenecker Clemens Aigner Christian R Kowol Siegfried Knasmueller Michael Grusch Be áta Szeitz Melinda Rezeli Balazs Dome Karin Sch Source Type: research
Pre-operative Neo-adjuvant Chemotherapy Related miRNAs as Key Regulators and Therapeutic Targets in Colorectal Cancer
CONCLUSION: In patients with colorectal cancer, miRNA expression in the tumoral regions before and after neoadjuvant therapy has represented a variable pattern. It has been shown that miRNA studies can be used to predict the clinical course and response to treatment with differences in expression levels. It has been concluded that specific miRNAs may be candidate biomarkers for colorectal cancer.PMID:37723961 | DOI:10.2174/1874609816666230816152744
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Orcun Yalav Ozge Sonmezler Kivilcim Eren Erdogan Ahmet Rencuzogullari Figen Doran Atil Bisgin Ibrahim Boga Source Type: research
Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial
CONCLUSIONS: The combination of sintilimab and anlotinib demonstrated durable efficacy and was generally well tolerated in patients with NSCLC and uncommon EGFR mutations who had received prior standard-of-care treatments. (ClinicalTrials.gov identifier: NCT04790409).PMID:37723837 | DOI:10.1002/cam4.6548
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Kaiyan Chen Yanjun Xu Zhiyu Huang Xiaoqing Yu Wei Hong Hui Li Xiaoling Xu Hongyang Lu Fajun Xie Jun Chen Youzu Xu Yun Fan Source Type: research
Ovarian cancer in the older patient: where are we now? What to do next?
Ther Adv Med Oncol. 2023 Sep 16;15:17588359231192397. doi: 10.1177/17588359231192397. eCollection 2023.ABSTRACTIn recent years, major advances have been made toward the individualization of epithelial ovarian cancer care, leading to an overall improvement of patient outcomes. However, real-life data indicate that the oldest populations do not benefit from this, due to aspects related to cancer (more aggressive histopathological features), treatment (i.e. frequently suboptimal), and the host (increased toxicities in patients with lower physiological reserve). A specific risk-benefit perspective should therefore be taken whe...
Source: Adv Data - September 19, 2023 Category: Epidemiology Authors: Fr édérique Rousseau Florence Ranchon Christophe Bardin Naoual Bakrin Vincent Lavou é Leila Bengrine-Lefevre Claire Falandry Source Type: research
Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
CONCLUSIONS: We demonstrate an increasing incidence of SBA over the study period. These data can help inform shared decision-making for optimal management of locoregional breast cancer and raise awareness of secondary angiosarcoma.PMID:37725702 | DOI:10.1097/COC.0000000000001045
Source: Clinical Genitourinary Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Bonny Chau Elizabeth T Loggers Lee D Cranmer Harveshp Mogal Jeremy M Sharib Edward Y Kim Stephanie K Schaub Kelly G Paulson Hannah M Linden Jennifer M Specht Janice N Kim Sara H Javid Michael J Wagner Source Type: research
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial
CONCLUSIONS: We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.PMID:37725572 | DOI:10.1158/1078-0432.CCR-23-1801
Source: Clinical Genitourinary Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Theresa Link Jens-Uwe Blohmer Wolfgang D Schmitt Jan Dominik Kuhlmann Marianne Just Michael Untch Oliver Stotzer Peter A Fasching Marc Thill Mattea Reinisch Andreas Schneeweiss Pauline Wimberger Sabine Seiler Jens Huober Christian Jackisch Kerstin Rhiem C Source Type: research
Neoadjuvant chemotherapy for advanced colonic cancer: standard of care or is the jury still out?
Br J Surg. 2023 Sep 19:znad281. doi: 10.1093/bjs/znad281. Online ahead of print.NO ABSTRACTPMID:37724780 | DOI:10.1093/bjs/znad281
Source: The British Journal of Surgery - September 19, 2023 Category: Surgery Authors: Peter G Vaughan-Shaw Martyn D Evans Source Type: research
Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
CONCLUSIONS: We demonstrate an increasing incidence of SBA over the study period. These data can help inform shared decision-making for optimal management of locoregional breast cancer and raise awareness of secondary angiosarcoma.PMID:37725702 | DOI:10.1097/COC.0000000000001045
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Bonny Chau Elizabeth T Loggers Lee D Cranmer Harveshp Mogal Jeremy M Sharib Edward Y Kim Stephanie K Schaub Kelly G Paulson Hannah M Linden Jennifer M Specht Janice N Kim Sara H Javid Michael J Wagner Source Type: research
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial
CONCLUSIONS: We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.PMID:37725572 | DOI:10.1158/1078-0432.CCR-23-1801
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Theresa Link Jens-Uwe Blohmer Wolfgang D Schmitt Jan Dominik Kuhlmann Marianne Just Michael Untch Oliver Stotzer Peter A Fasching Marc Thill Mattea Reinisch Andreas Schneeweiss Pauline Wimberger Sabine Seiler Jens Huober Christian Jackisch Kerstin Rhiem C Source Type: research
The Prognostic Significance of P16 Immunohistochemical Expression Pattern in Women with Invasive Ductal Breast Carcinoma
CONCLUSIONS: Our study demonstrated that p16 protein expression increased in ER-positive tumor tissue from patients with invasive ductal breast carcinoma. However, no correlation was found between the p16 protein expression and the other clinicopathological features.PMID:37724141 | PMC:PMC10505467 | DOI:10.52547/rbmb.12.1.83
Source: Mol Biol Cell - September 19, 2023 Category: Molecular Biology Authors: Alireza Rezaei Navidreza Shayan Saman Shirazinia Sara Mollazadeh Negin Ghiyasi-Moghaddam Source Type: research
CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway
In conclusion, our study shows that CAB39 counteracts the killing of cisplatin by enhancing the autophagy of BC cells to damaged mitochondria and other organelles to alleviate the damage of cells caused by harmful substances such as ROS.PMID:37726090 | DOI:10.1016/j.freeradbiomed.2023.09.017
Source: Free Radical Biology and Medicine - September 19, 2023 Category: Biology Authors: Dongyang Gao Runchang Wang Yuwen Gong Xiaoquan Yu Niu Qian Enguang Yang Guangrui Fan Junhai Ma Chaohu Chen Yan Tao Jianzhong Lu Zhiping Wang Source Type: research
